Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts
02:50am, Friday, 13'th Mar 2026
Keros Therapeutics, Inc. (NASDAQ: KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
08:00am, Monday, 09'th Mar 2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
01:01pm, Friday, 06'th Mar 2026
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
06:10pm, Wednesday, 04'th Mar 2026
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.14 per share a year ago.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 04'th Mar 2026
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
Keros Therapeutics Appoints Charles Newton to its Board of Directors
04:01pm, Thursday, 26'th Feb 2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
04:01pm, Wednesday, 18'th Feb 2026
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
10:42am, Wednesday, 18'th Feb 2026
KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
10:20am, Tuesday, 27'th Jan 2026
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-bet
Is KROS' KER-065 the Next Breakthrough in DMD Space?
10:16am, Monday, 26'th Jan 2026
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
10:10am, Friday, 16'th Jan 2026
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
10:16am, Thursday, 15'th Jan 2026
KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close
08:35am, Wednesday, 31'st Dec 2025
AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.
KROS or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 30'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents
